Barclays’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Barclays’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,300	Closed	-$88K	–	7398
2019 Q2	$88K	Buy	+13,300	New	+$50.6K	﹤0.01%	5783
2018 Q4	–	Sell	-200	Closed	-$4K	–	7629
2018 Q3	$4K	Sell	200 -200	-50%	-$5.06K	﹤0.01%	6857
2018 Q2	$13K	Hold	400	–	–	﹤0.01%	6437
2018 Q1	$15K	Buy	400 +68	+20%	+$4.47K	﹤0.01%	6538
2017 Q4	$26K	Buy	+332	New	+$24.6K	﹤0.01%	6165

Barclays's MLNT Position: Q1 2020 in Review

Barclays sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 13 shares.

Barclays first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $498K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Barclays reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Barclays sold 13 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
Barclays first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Barclays's Melinta Therapeutics, Inc. Common Stock position peaked at $498K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.